Sign inJoin waitlistJoin the waitlist

Ana Paez

Physician · Driscoll Childrens Hospital

Credentials: · · · ·

History

Driscoll Childrens Hospital
2019–Present

Pediatric Endocrinology
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine
2010–2013
Pediatrics
University of Texas Health Science Center at San Antonio
2007–2010
Ponce Health Sciences University School of Medicine
2003–2007

Research

The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach
Review · Current Diabetes Reviews · 2011 · 240 citations
Coordinated defects in hepatic long chain fatty acid metabolism and triglyceride accumulation contribute to insulin resistance in non-human primates
PLoS ONE · 2011 · 34 citations
Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas
JCI Insight · 2019 · 24 citations

Glenn Halff
3 papers
Gregory Abrahamian
3 papers
Ralph DeFronzo
3 papers
Ashwin Adivi
1 paper
DP
Dennis Peppas
1 paper
Devjit Tripathy
1 paper
DV
Diana Villarreal
1 paper
Elizabeth Roeder
1 paper
George Powers
1 paper
HV
Humberto Villarreal
1 paper · 1 as a resident
Jane Lynch
1 paper
LQ
Larry Quang
1 paper

Clinical trials

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Site PI · Not yet recruiting · Phase 3
Eli Lilly and Company
2026–2030
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Site PI · Not yet recruiting · Phase 3
Eli Lilly and Company
2026–2032
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2026–2028
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2024–2027